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ABSTRACT
Introduction: An innovative computational
model was developed to address challenges
regarding the evaluation of treatment sequen-
ces in patients with relapsing–remitting multi-
ple sclerosis (RRMS) through the concept of a
‘virtual’ physician who observes and assesses
patients over time. We describe the implemen-
tation and validation of the model, then apply
this framework as a case study to determine the
impact of different decision-making approaches
on the optimal sequence of disease-modifying
therapies (DMTs) and associated outcomes.
Methods: A patient-level discrete event simu-
lation (DES) was used to model heterogeneity in
disease trajectories and outcomes. The evalua-
tion of DMT options was implemented through
a Markov model representing the patient’s dis-
ease; outcomes included lifetime costs and
quality of life. The DES and Markov models
underwent internal and external validation.
Analyses of the optimal treatment sequence for
each patient were based on several decision-
making criteria. These treatment sequences
were compared to current treatment guidelines.
Results: Internal validation indicated that
model outcomes for natural history were con-
sistent with the input parameters used to
inform the model. Costs and quality of life
outcomes were successfully validated against
published reference models. Whereas each
decision-making criterion generated a different
optimal treatment sequence, cladribine tablets
were the only DMT common to all treatment
sequences. By choosing treatments on the basis
of minimising disease progression or number of
relapses, it was possible to improve on current
treatment guidelines; however, these treatment
sequences were more costly. Maximising cost-
effectiveness resulted in the lowest costs but was
also associated with the worst outcomes.
Conclusions: The model was robust in gener-
ating outcomes consistent with published
models and studies. It was also able to identify
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optimal treatment sequences based on different
decision criteria. This innovative modelling
framework has the potential to simulate indi-
vidual patient trajectories in the current treat-
ment landscape and may be useful for
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Key Summary Points
In health economics, Markov models are
widely used to represent
relapsing–remitting multiple sclerosis
(RRMS), but usually evaluate only a single
line of treatment.
Here, we report on the implementation
and validation of an innovative
computational model designed to address
challenges regarding treatment sequences
in patients with RRMS. We also apply this
modelling framework as a case study to
determine the impact of different
decision-making approaches on the
optimal treatment sequence and
associated outcomes.
Internal and external validation of our
model showed that outcomes were
consistent with those of existing Markov
models and the published literature.
Each decision-making criterion generated
a different optimal treatment sequence; it
was possible to improve patient outcomes
compared with current treatment
guidelines.
The model presented here has the
potential to simulate individual patient
trajectories and may be useful in
supporting treatment switching decisions
as well as informing future clinical
guidelines.
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoim-
mune-mediated inflammatory disease of the
central nervous system that affects an estimated
2.8 million people worldwide [1, 2]. Of these,
approximately 85% are diagnosed with relaps-
ing–remitting multiple sclerosis (RRMS), which
is characterized by periodic acute exacerbations
of disease activity (relapses) that can lead to
neurological disability over the patient’s life-
time [2]. Several disease-modifying therapies
(DMTs), targeted at delaying the progression of
disability, have received regulatory approval
over the past 20 years, significantly increasing
the number of treatment options and improv-
ing quality of life for patients [3]. The number of
DMTs on the market, coupled with the reality
that RRMS requires long-term treatment
wherein most patients will switch DMTs at least
once over the course of their disease, poses
challenges for physicians regarding the choice
of, and appropriate times to switch, a patient’s
DMT [4, 5]. Additionally, health economists
and policymakers are challenged with how to
evaluate DMTs appropriately in order to capture
the heterogeneity of disease trajectories and
treatment patterns in patients with RRMS [6, 7].
Currently, the majority of health economic
models for RRMS are Markov models, which
typically evaluate a single line of treatment in a
cohort of patients with RRMS [6, 7]. As such,
these models are not able to address questions
regarding treatment sequencing. Here we
describe an approach, based on an innovative
model framework, designed to address the
challenges regarding treatment sequences in
RRMS. This approach replicates the process of
clinical decision-making, through simulating a
‘virtual’ physician who makes treatment deci-
sions according to his or her evolving under-
standing of a patient’s disease as it manifests
over time. As a computational model of physi-
cian behaviour, this approach has the potential
to simulate individual patient trajectories in the
current treatment landscape in order to support
treatment switching and treatment positioning
decisions in RRMS.
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In the current paper, the implementation of
this innovative approach to modelling treat-
ment sequences in patients with RRMS is
described in detail, along with results of several
validation exercises. In addition, the modelling
framework was applied as a case study to
explore the impact of different decision-making
criteria on the optimal sequence of DMTs, as
well as to determine the costs, quality of life,




Disability worsening in RRMS is commonly
assessed using the Expanded Disability Status
Scale (EDSS). An EDSS score of 6.0 (on a scale
from 0 to 10) is used to define a disabling level
of disease [8]; time from disease onset to
EDSS 6.0 (ttEDSS6), without treatment, can be
regarded as a proxy for severity of disease
[9, 10]. Patients with RRMS have heterogeneous
disease trajectories, i.e. differing ttEDSS6 or
severities. The core assumption underlying this
model is that physicians use DMTs to slow dis-
ability progression and prolong ttEDSS6. Each
DMT involves potential benefits and potential
risks and the choice regarding treatment con-
sists of a trade-off for each individual patient;
the probability of serious adverse events (SAEs)
may be identical but the potential benefits
associated with the additional treatment effi-
cacy may be greater for more severe patients
who are deteriorating more rapidly [11]. As
such, the physician’s expectation of severity
drives treatment switching decisions.
The model centres on the patient–physician
interaction during iterative outpatient visits
(Fig. 1). Initially (1), a patient is simulated with
characteristics including age at disease onset
and sex. Severity (ttEDSS6 without treatment),
time to non-MS related death, and relapse rate
are then assigned to the patient on the basis of
these simulated characteristics. During each
visit, the virtual physician observes relapses,
disability worsening, and adverse events (AEs)
(2a) and forms/revises their expectation about
the patient’s disease severity and probability of
response to treatment (i.e. prior/posterior) on
the basis of these observations (2b). The
observed clinical outcomes (2a) also drive the
decision whether to switch treatment when
either tolerability or response is insufficient,
and when this occurs the current expectation
(prior) of severity is used to determine the
optimal DMT for the patient (2c/d). Note, as in
clinical reality, the actual severity level and all
future events simulated by the model are
unknown to the physician.
The optimal DMT at treatment initiation and
subsequent switch is identified using a Markov
model which represents RRMS (2c). This Mar-
kov model yields the expected outcomes for
each DMT, from which the physician selects the
best option (2d) based on a specific decision
rule. The clinical outcomes and patient trajec-
tory are then simulated (3) on the basis of the
treatment selected as the optimal option (at 2d).
The process continues until treatment with
DMTs is terminated (e.g. due to death, attaining
EDSS7 or EDSS8 as determined by the model, or
reaching the maximum number of lines of
treatment). This approach ultimately yields an
optimal DMT sequence for each individual
patient inclusive of costs and quality of life
outcomes associated with the patient’s disease
trajectory.
Model Implementation
The virtual physician model was built as a
patient-level discrete event simulation (DES) in
order to (1) capture the heterogeneity in disease
trajectories and outcomes, (2) resemble the
patient–physician interaction during visits, and
(3) record individual patient histories. A sche-
matic overview of the model is shown in Fig. 2.
The model outcomes included costs and quality
of life (represented as quality-adjusted life years,
QALYs) related to disease management linked
to EDSS scores, relapses, and SAEs. The model
was programmed in R [12]. Please refer to the
Supplemental Materials for a more detailed
description of the methods, including calcula-
tions and model inputs.
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Disease Trajectory
For each simulated patient, the process com-
mences at the diagnosis of RRMS. At this point,
sex and age at onset, randomly drawn from
independent statistical distributions in the
patient population of interest, are assigned to
the patient. Next, the patient’s disease trajec-
tory, a list of events that may happen to the
patient over the natural history of the disease, is
simulated (on the basis of the British Columbia
Multiple Sclerosis [BCMS] registry data [13, 14]).
For each specific treatment, the disease trajec-
tory for relapses and EDSS progression is deter-
mined through application of a treatment effect
to the natural history. The treatment effect
applied is based on a published network meta-
analysis (NMA) of cladribine tablets versus
comparators [15].
The modelled events include the time of (1)
the next EDSS step, (2) a relapse, (3) an SAE, (4)
the next routine visit, and (5) death due to
causes other than MS. Secondary progressive MS
(SPMS) is not explicitly modelled here as it is
considered a later stage of RRMS [16] and con-
version to SPMS has little or no implications for
costs and QALYs [17, 18].
The time of the next EDSS step is based on
the patient’s severity (ttEDSS6), which is ran-
domly drawn from a distribution of patient
severities stratified by sex and age at onset [13].
Fig. 1 Visualization of the iterative treatment decision process. DMT disease-modifying therapy, ttEDSS6 time from disease
onset to Expanded Disability Status Scale state 6, MS multiple sclerosis
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The time of a relapse is based on a patient’s
individual annualised relapse rate (ARR). In the
first 5 years following diagnosis, the ARR is
determined by the patient’s simulated severity
[14]. Beyond 5 years, disability worsening and
relapses are modelled independently as no data
were identified regarding the relationship
between EDSS and relapses in natural history
[14, 19]. In addition, the ARR is assumed to
decrease over the course of the disease on the
basis of the age at onset. A relapse can either be
severe (requiring hospitalisation) or non-severe.
The time of an SAE is based on incidence rates
which were sourced from pivotal trials [20–29].
Furthermore, the probability of progressive
multifocal leukoencephalopathy (PML), a
potentially fatal complication first linked with
natalizumab treatment and now thought to
occur with a variety of DMTs, increases over
time and is modelled on the basis of the
patient’s anti-John Cunningham virus (JCV)
antibody serological status and the duration of
exposure to natalizumab [15, 30]. Routine visits
take place at regular time intervals, by default
set at 1 year. The simulation ceases for each
patient only at the point when the patient dies,
either from MS (i.e. when EDSS10 is reached) or
from other causes. The time of death due to
causes other than MS is calculated given the
patient’s age and sex, using the life expectancy
of the general population [16].
Following an event, the disease trajectory is
modified in one of two ways: (1) if the event
does not trigger a switch of treatment, an
updated time is simulated for the event which
occurred with times for all other events
remaining unchanged or (2) if the event leads to
a treatment switch, the disease trajectory is re-
simulated to reflect the treatment effects and
SAEs associated with the new treatment. When
a patient reaches the point of DMT termination,
the patient is ‘switched’ to natural history. From
this point, the trajectory only contains relapses
and EDSS steps to allow the calculation of life-
time costs and effects; SAEs associated with
DMTs are no longer modelled. In natural his-
tory, it is assumed that no further treatment
switches are possible.
Switching Indicators
Re-evaluation of the treatment decision fol-
lowing an event is triggered by inadequate
effectiveness, safety concerns such as the
occurrence of a SAE, or an unacceptable PML
risk. For effectiveness, the model switches a
proportion of patients on the basis of
Fig. 2 Schematic overview of the virtual physician model
implementation. The current events determine what
occurs at each visit (based on the earliest of the current
events). Update simulation clock and age: the time and age
of the patient are updated to reflect the passage of time to
the current event. DMT disease-modifying therapy, EDSS
Expanded Disability Status Scale, SAE serious adverse
event, PML progressive multifocal leukoencephalopathy
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assumptions regarding relapses and/or EDSS
worsening (see Supplemental Table 10).
Updating the Prior of Severity
The physician’s expectation (prior) of a
patient’s severity is updated at each visit and
based on observations about EDSS progression.
The prior of severity is implemented by 11
severity groups, each representing a different
ttEDSS6 in 5-year bands: (1)[0–5 years,
(2)[5–10 years,…,11)[50–55 years. The prior
of severity gives a probability distribution for
the patient residing in each of these severity
groups. These probabilities are collectively
exhaustive, i.e. the probabilities must sum to
one. The virtual physician’s prior of severity at
baseline is equal to the distribution of severity
groups from which the patient’s individual
severity is drawn (e.g. male, onset age 35 years).
The approach taken to update the prior of
severity as the physician interacts with the
patient over time is described in the Supple-
mental Materials.
Determination of the Optimal DMT
At treatment initiation or switch, the alterna-
tive treatment options are evaluated, under the
assumption that a patient can only receive any
DMT once. A Markov model component [16],
which represents the decision process con-
ducted by the physician, is used to identify the
optimal DMT given the patient’s current age,
sex, and expected ARR given disease duration
and the prior of severity (the Markov model
makes use of the same clinical parameters as the
DES but uses average/population values rather
than individual estimates). The Markov model
consists of 11 health states ranging from EDSS 0
to 9 plus death and is evaluated for each of the
EDSS severity groups and for all available DMT
options. The transition probabilities are depen-
dent on the severity and are adjusted by a
treatment effect (see Supplementary Materials
for more detail).
For each available treatment and for each of
the severity groups, the Markov model predicts
the time the patient would spend in each EDSS
state until the end of the time horizon (set at
5 years on the basis of a Delphi study [31]) or
death. The Markov model generates costs and
QALYs related to treatment, disease manage-
ment, relapses, and AEs. The outcomes associ-
ated with each possible treatment are
determined as a weighted average of the out-
comes associated with each severity group using
the distribution of patient severities (prior of
severity) as weights. This yields the expected
outcomes for the patient for each treatment.
The virtual physician then determines the
optimal treatment based on a specific decision
rule. Decision rules that may be considered
include minimising number of relapses, max-
imising the time to disability progression, and
cost-effectiveness (best value for money).
Model Validation
Both the DES and the Markov model were sub-
jected to internal and external validation.
Internal validation assessed whether model
outcomes for natural history were in line with
the input parameters used to inform the model.
The DES model for natural history was based on
the BCMS registry data [13, 14, 32]. The relapse
rate and ttEDSS6 were validated against their
original sources, including modelling the med-
ian simulated ttEDSS6, the impact of age at
onset and sex on simulated ttEDSS6, and
relapses conditional on disease duration, age at
onset, and severity. External validation com-
pared costs and quality of life outcomes from
the DES model against outcomes produced
using the model described in a recently pub-
lished cost-effectiveness analysis [33]. This ref-
erence is a cohort-based Markov model that
compared alemtuzumab, cladribine tablets,
natalizumab, and natural history (best sup-
portive care, BSC). In the DES, these four treat-
ment strategies were evaluated, one at a time;
after discontinuation of active treatment
patients were moved to BSC.
The Markov component of the treatment-
sequencing model is crucial as it determines the
patient’s next treatment. As such, a separate
validation was undertaken and the Markov
component was validated against the reference
model developed for cost-effectiveness purposes
[33]. This validation comprised two elements:
Adv Ther
first, the progression rates in natural history
were compared to published progression rates
[16], then the cost and QALY outcomes were
compared to the reference model [33].
Case Study: Modelling the Optimal
Treatment Sequence and Assessing
the Impact of Different Decision-Making
Criteria
A case study was developed to model how dif-
ferent decision-making criteria identified the
optimal sequence of DMTs, along with the
associated impact on costs and quality of life
outcomes, as well as hospital resource usage. A
cohort of 1500 patients was simulated in the
DES over their future lifetime; treatment deci-
sions were re-evaluated annually over a 5-year
time horizon, which is a typical time horizon
for decision-making according to the Delphi
study with neurologists [31]. The analyses
included a set of nine DMTs (alemtuzumab,
cladribine tablets, dimethyl fumarate, fin-
golimod, glatiramer acetate, interferon beta-1a,
natalizumab, ocrelizumab, and teriflunomide)
as well as the option of no treatment.
Current Treatment Guidelines
Initially, a sequence based on current treatment
guidelines was estimated using the National
Health Service (NHS) England’s ‘Treatment
Algorithm for Multiple Sclerosis Disease-Modi-
fying Therapies’ [34]. To find a suitable scenario
for the population simulated in the model, it
was assumed that at the start of the treatment
sequence, the patient is diagnosed with RRMS
on the basis of one relapse in the last 2 years and
radiological activity. Additionally, it was
assumed that the physician would not choose
interventions that are indicated in the algo-
rithm as being high risk for that line of therapy.
As such, the chosen guideline treatment
sequence was (1) interferon beta-1a; (2)
cladribine tablets; (3) ocrelizumab. The NHS
report gives no recommendations of optimal
DMTs after third-line treatment; therefore, the
analyses presented here focused on the first
three lines of treatment only.
Decision Rules
Three different decision rules were selected for
this case study; the optimal treatment sequence
for each was calculated and compared to cur-
rent treatment guidelines. The ‘number of
relapses’ criterion selects the optimal DMT
based on the lowest relative risk of relapses. The
‘number of EDSS steps’ criterion estimates the
optimal DMT based on the lowest average EDSS
value at the end of the 5-year time horizon. The
‘cost-effectiveness’ criterion uses the Markov
model component to calculate the optimal
DMT over the 5-year period based on the
highest number of QALYs with an associated
incremental cost-effectiveness ratio (ICER)
below the cost-effectiveness threshold. This is
implemented as the treatment that yields the
highest expected net monetary benefit (NMB =
QALYs 9 willingness-to-pay threshold - costs),
calculated using a willingness-to-pay threshold
of £30,000 per QALY gained.
Estimating Resource Usage
Three DMTs (alemtuzumab, natalizumab, and
ocrelizumab) included in the model require
infusion visits for patients. These visits are
associated with additional resource use and
costs, which are included in the model, but also
require the availability of physical capacity in
the hospital (e.g. chair time) for the duration of
the infusion. The capacity required over time,
in terms of proportion of patients on treatment
requiring infusion visits, was calculated for the
current treatment guidelines and optimal
sequence of DMTs based on each of the three
decision rules presented above. These calcula-
tions assumed a fixed cohort of patients
requiring capacity and no newly diagnosed
patients entering the model.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human participants or animals performed





Tremlett et al. reported a median ttEDSS6 of
32.6 years (95% confidence interval [CI] 29.2,
36.0) for patients with RRMS [13]. Before
adjustment for background mortality (compet-
ing risks), the DES provided a good prediction of
the median ttEDSS6 (32.5 years; 95% credible
interval [CrI] 32.0, 33.0) based on 25,000 sim-
ulated patients. A Cox model, fitted to the
simulated ttEDSS6, predicted the hazard ratio
(HR) of ttEDSS6 due to age at disease onset and
sex well (Table 1).
After correction of the ttEDSS6 for back-
ground mortality, the severity at baseline was
re-simulated for 25,000 patients. The median
ttEDSS6 after correction was 26.8 years (mean
27.7; 95% CrI 27.5, 27.9). The DES was then run
for 2000 patients given natural history. A Cox
model was fitted on the ttEDSS6 censoring
patients who died before reaching EDSS6. The
median ttEDSS6 reached by patients in the DES
(27.1 years, 95% CI 26.0, 28.2) was similar to
the simulated values at baseline, suggesting that
disability worsening until EDSS6 was imple-
mented correctly in the DES.
In terms of relapse data, the mean ARR from
the DES was 0.24 (median 0.22; interquartile
range [IQR] 0.14, 0.31), which was similar to the
ARR of 0.23, calculated as 11,722 events/(mean
follow-up [20.6 years] 9 patients [2477])
observed by Tremlett et al. [14]. This shows that
the model predicted relapses appropriately.
DES External Validation
The results of the comparisons of alemtuzumab,
cladribine tablets, natalizumab, and BSC are
shown in Table 2. Overall, the results of the DES
model were in a similar range to the results of
the reference model. The most important dif-
ferences were those associated with drug costs,
relapse-related costs and QALYs, and AE-related
costs and QALYs. Furthermore, the disease
management costs associated with alem-
tuzumab and cladribine tablets were higher in
the DES than in the reference model. The dif-
ferences in drug and disease management costs
are mainly explained by higher discontinuation
rates in the DES than in the reference model.
Differences in AEs are explained by including
only severe AEs in the DES. The average ttEDSS6
was 26.4 years in the DES compared to
20.9 years in the reference model; this would be
expected from the relatively more severe popu-
lation used in the latter.
Markov Model
The proportions of patients who had not
reached EDSS6 over time are displayed in
Appendix Fig. 1. The weighted average across all
severity groups produced by the Markov model
Table 1 DES internal validation results on time to EDSS6
Reference model HR (CrI) [13] DES HR (CrI)
Onset age (years)
\ 20 1 1
20 to\ 30 1.21 (0.95–1.51) 1.20 (1.14, 1.25)
30 to\ 40 1.82 (1.44–2.30) 1.73 (1.65, 1.82)
40 to\ 50 1.95 (1.47–2.58) 1.90 (1.79, 2.01)
C 50 2.22 (1.49–3.31) 2.14 (1.96, 2.34)
Sex
Female/male 1:1.11 (0.96–1.30) 1:1.08 (1.04, 1.11)
DES discrete event simulation, HR hazard ratio, EDSS6 Expanded Disability Status Scale state 6, CrI credible interval
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closely matched the data from Palace et al. until
year 5 [16]. Beyond this point, the proportion of
patients who had not reached EDSS6 declined
more slowly in our model.
Appendix Fig. 2 displays the average time
spent in each health state for a time horizon of
25 years. These outcomes are well aligned
between the models, although patients in the
reference model spent relatively more time in
EDSS6 and EDSS8 compared to the Markov
component of our model, while they spent rel-
atively less time in EDSS4 and EDSS5. When the
modelled cohort starts at EDSS3, patients in the
reference model again spent more time in
EDSS6 and EDSS8 than patients in our model.
The most striking difference was observed for
EDSS state less than 3: no patients resided in
EDSS0 to EDSS2 in our Markov model since no
backward transitions were allowed, as compared
to the reference model where patients spent
approximately 5 years in EDSS0 to EDSS2 within
a 25-year time horizon.
The outcomes of the Markov component of
our model were also compared to the outcomes
from the reference Markov model [33]. The
results of the validation for a time horizon of
25 years are shown in Table 3. The outcomes of
our Markov model are reasonably aligned with
the outcomes of the reference model. The most
prominent differences are (1) life years and
associated QALYs are lower in our Markov
model because MS-related mortality was mod-
elled differently, (2) the number of relapses in
natural history and the associated costs and
QALYs are higher in our Markov model because
it used a more detailed method to calculate
relapses in natural history; specifically the
number of relapses with treatment are lower
Table 2 DES external validation results










Total costs () 77,480 79,735 118,148 128,019 133,075 144,566 250,904 193,151
Drug
acquisition
0 0 50,608 49,390 64,076 59,876 118,392 73,900
Drug
administration
0 0 0 0 4874 4941 55,622 37,545
Drug
monitoring
0 0 761 835 777 1118 4235 2854
Total drug-
related
0 0 51,368 50,225 69,727 65,935 178,250 114,299
AE-related 0 0 348 33 372 0 297 51
Relapse-related 9198 15,026 6319 13,437 5709 14,096 7319 14,048
EDSS-related 68,282 64,708 60,113 64,324 57,267 64,535 65,038 64,752
Total QALYs 21.258 21.049 24.615 24.117 25.834 22.844 22.730 22.629
AE-related 0 0 - 0.008 0.000 - 0.015 0.000 - 0.004 - 0.001
Relapse-related - 0.041 - 0.161 - 0.029 - 0.143 - 0.027 - 0.150 - 0.034 - 0.150
EDSS-related 21.300 21.211 24.652 24.260 25.876 22.993 22.769 22.780
DES discrete event simulation, AE adverse event, EDSS Expanded Disability Status Scale, QALY quality-adjusted life year
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because no discontinuation is assumed, and (3)
the treatment costs of natalizumab, the only
continuously administered DMT included in
this model, are considerably higher in our
Markov model because no discontinuation was
assumed.
Case study: Modelling the Optimal
Treatment Sequence and Assessing
the Impact of Different Decision-Making
Criteria
Figure 3 presents the optimal treatment
sequences based on the current treatment
guidelines as well as for each of the three deci-
sion criteria. As illustrated, each generated a
different optimal treatment sequence. Cladrib-
ine tablets is the only DMT that was common to
all sequences; however, its positioning within
treatment lines changed with the choice of
scenario. The sequences based on minimising
the number of relapses or EDSS steps were sim-
ilar, with the second- and third-line treatments
(natalizumab and ocrelizumab) switching. The
sequence optimising for cost-effectiveness had a
common DMT for all patients (glatiramer acet-
ate) for first-line therapy. For second and sub-
sequent treatment lines, different patients
receive different treatments.
Table 4 presents the impact of the treatment
sequences in terms of the proportion of patients
reaching EDSS6, time spent in the model, costs,
and QALYs. The results indicate that the lowest
Table 3 Markov model validation results based on a 25-year time horizon

















Life years 24.24 21.70 24.24 21.92 24.24 21.98 24.24 21.96
Number of
relapses
4.77 5.20 3.18 2.03 2.94 1.55 3.82 1.64
Total costs
()
39,397 34,377 84,953 80,432 101,891 98,063 210,065 511,178
Treatment-
related
0 0 51,378 52,512 69,746 71,201 174,176 484,105
AE-related 0 188 348 213 372 226 297 202
Relapse-
related
7751 8529 5058 3334 4518 2537 5877 2691
EDSS-
related
31,646 25,660 28,168 24,373 27,255 24,100 29,715 24,181
Total
QALYs
15.403 14.184 17.194 15.516 17.728 15.992 16.470 15.803
AE-related 0.000 - 0.060 - 0.008 - 0.072 - 0.015 - 0.082 - 0.004 - 0.103
Relapse-
related
- 0.035 - 0.091 - 0.023 - 0.036 - 0.021 - 0.027 - 0.028 - 0.029
EDSS-
related
15.438 14.335 17.225 15.624 17.764 16.105 16.503 15.935
EDSS Expanded Disability Status Scale, AE adverse event, QALY quality-adjusted life year
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proportion of patients reaching EDSS6 (1.07%)
occurred when the treatment decision was
made based on the sequence most likely to
minimise the number of EDSS steps. Choosing
treatments to minimise the number of relapses
in turn maximised the time spent in the model,
as well as QALYs, but this sequence has the
largest associated costs. Choosing the optimal
treatment based on cost-effectiveness was asso-
ciated with the lowest costs and the lowest
QALYs. The main differences between the
treatment sequences in terms of costs come
from drug acquisition and administration. As
higher costs were associated with better out-
comes in these scenarios, it suggests that the
more efficacious treatments in terms of the
number of relapses and reducing the number of
EDSS steps are also more expensive. Addition-
ally, the second- and third-line treatments in
these sequences (natalizumab and ocrelizumab)
require infusions and are among the most
expensive treatments both in terms of annu-
alised drug and administration costs.
Figure 4 presents the results of the scenarios
on a cost-effectiveness plane relative to the
current treatment guidelines. This indicates
that at the illustrated threshold of £30,000 per
QALY gained, the optimal sequences for min-
imising EDSS steps or relapses were not cost-ef-
fective compared to the current treatment
guidelines sequence. The sequence obtained
from optimising cost-effectiveness decision cri-
teria is cost-effective at this threshold; however,
it does reduce the number of QALYs (at reduced
cost) for patients compared to the sequence
based on current guidelines.
Figure 5 presents the number of patients on a
treatment that require an infusion visit over
time. When choosing the optimal treatment
sequence based on cost-effectiveness, no treat-
ments that require an infusion visit are inclu-
ded; this is likely due to the increased cost in
terms of drug acquisition and administration
associated with these treatments. The graphs
based on minimising EDSS steps or relapses
decision criteria are similar. This can be
explained by the similarity in the treatment
sequences (see Fig. 5), with the second and third
treatment lines alternating between the two
sequences. In all cases, the number of incident
patients requiring infusion visits peaks at 10–-
20 years after treatment initiation.
DISCUSSION
New modelling approaches are needed to
address questions regarding treatment sequen-
ces in RRMS, including what decisions rules are
currently used when considering the bene-
fit–risk profiles of different DMTs in clinical
settings and what thresholds should be used to
determine that a DMT is not performing con-
sistent with expectations. The approach descri-
bed in the current paper is proposed to help
decision-makers address these complex ques-
tions and provides an innovative framework for
the explicit modelling of treatment sequences
in RRMS. The model focuses not only on what
treatment a patient will, or should, switch to
but also on when a patient should switch treat-
ment. The conceptualisation of the (virtual)
physician as someone who updates his/her view
of a patient’s expected severity each time he/she
observes the patient was introduced to reflect
the fact that physicians develop an
Fig. 3 Optimal treatment sequences using different treat-
ment decision criteria. Note that proportions do not sum
to 100% after the first treatment because patients may
drop out of treatment or the model (because of death).
EDSS Expanded Disability Status Scale
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understanding of the patient over time and, in
theory, can make more informed treatment
decisions as time progresses.
The internal validation of the DES showed
that disease severity, survival, and number of
relapses are appropriately simulated for natural
history. It is worth noting that the narrower
CrIs calculated by the DES compared to the
reference model can be partially attributed to
the large number of patients simulated. The
external validation showed that the outcomes
of the DES and Markov model matched the
reference models reasonably well, except for
some differences which relate to modelling
choices. The most prominent difference was the
discontinuation rate, which was modelled using
a user-adjustable decision rule in the DES and
may have resulted in different discontinuation
rates than those used in the Markov model. The
relapse outcomes also differed between the
models; however, given the ARR in the DES has
been validated against the average relapse rate
from the BCMS registry, we are confident that
the DES simulates relapses appropriately. Dif-
ferences were also observed in natural history
progression of the Markov model compared to
the reference cost-effectiveness model [16, 33].
These are as expected as Palace et al. [16] used a
selection of patients from the BCMS registry
with relatively severe disease (at least two
relapses in the last 2 years), whereas the severity
groups in our model captured patients from the
BCMS registry without any requirements for
disease activity. In addition, our Markov model
provided no allowance for backward transitions
(i.e. EDSS improvements) because these are
considered temporary improvements, whereas
backward transitions are included in the refer-
ence model [16]. Any other differences in Mar-
kov model outcomes are as expected and are
attributable to different inputs and modelling
choices. Overall, the results of the Markov
model are considered robust and reliable.












1.80 2.20 1.27 1.07
Years in model 21.38 18.99 22.13 22.09
Total costs (£) 293,912 173,730 350,300 348,195
Drug acquisition 254,665 145,160 269,355 270,954
Drug administration 9429 487 49,042 45,714
Drug monitoring 3973 4540 5123 4909
AE-related 125 40 171 177
Relapse-related 3235 3508 2765 2687
EDSS-related 22,484 19,995 23,845 23,754
Total QALYs 16.56 14.65 17.50 17.47
AE-related - 0.00 - 0.04 - 0.00 - 0.00
Relapse-related - 0.04 - 0.04 - 0.03 - 0.03
EDSS-related 16.60 14.73 17.53 17.50
EDSS6 Expanded Disability Status Scale state 6, QALY quality-adjusted life year, AE adverse event
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One of the challenges with patient-level DES
are the data requirements. The current imple-
mentation of the model used published, aggre-
gate data and the key assumptions were
validated in a Delphi study [31]. Although nat-
ural history was consistently based on the BCMS
registry [13, 14, 32] and the validation process
showed that the model can reproduce the pub-
lished population level estimates, the use of
aggregate data to populate the DES means that
the covariance between simulated patient
characteristics could not be included, neither
could any relation between disability worsening
and relapses nor a correlation between treat-
ment effects within a patient. As such, the
individual outcomes might be incorrect. A
possible next step in the development of this
model would be to fill these gaps using data
from real-world studies. For example, magnetic
resonance imaging test results were omitted
from the current model because, as a result of
Fig. 4 Results based on different treatment decision
criteria relative to the current treatment guidelines
sequence. EDSS Expanded Disability Status Scale
Fig. 5 Number of patients on treatments requiring infusion visits by treatment decision criteria. NMB net monetary
benefit, EDSS Expanded Disability Status Scale
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the high correlation with relapses, it was
deemed inappropriate to include them in the
patient-level simulation, based on published
aggregate data only [31]. However, the inclu-
sion of radiology in the DES next to relapses and
disability worsening, as well as in the decision
rule for treatment switching, may potentially
improve the model. Similarly, the probability of
PML was only modelled for natalizumab treat-
ment; real-world data on the incidence of PML
in other DMTs for RRMS would be useful.
The virtual physician uses a likelihood
function to update his/her belief of the patient’s
disease severity. This likelihood function
describes what a physician learns about the
patient’s severity when the physician makes
observations regarding disability worsening.
Currently, a Gompertz distribution with a shape
parameter of 0.1 was used to model this rela-
tionship between EDSS steps and a patient’s
severity. This assumption was based on the
progressive nature of RRMS and the assumed
uncertainty in this relationship. Additional
research is required to determine the accuracy
of the current likelihood function and/or pro-
pose suitable alternatives. One of the key chal-
lenges in modelling treatment sequences in
RRMS, as well as other autoimmune diseases
including rheumatoid arthritis, is locating evi-
dence for the effectiveness of treatments when
given in later lines [17, 35, 36]. Whereas this
model does not present a solution to this data
gap, modelling treatment sequences in more
detail makes knowledge gaps apparent and
enables researchers to investigate the impact on
treatment decisions. In addition, the physi-
cian’s choice of treatment will be affected by
factors other than perception of disease severity,
including patient choice, lifestyle, pregnancy,
and co-morbidities; further research is required
to develop the model to incorporate these
factors.
This innovative framework enables the user
to explore different decision criteria for choos-
ing the optimal treatment strategy. In the case
study, it was possible to improve on the current
treatment guidelines strategy in terms of
reducing the proportion of patients who reach
EDSS6, duration of time spent on the first three
lines of treatment, and associated quality of life.
This was accomplished by choosing the optimal
treatment sequence based on minimising the
expected number of EDSS steps or relapses.
However, this improvement does come at a
financial cost. The treatments that minimise
EDSS steps and relapse rates are more costly in
terms of drug acquisition and administration
costs. Optimising treatment by maximising
cost-effectiveness is the least expensive treat-
ment sequence, but also has the lowest QALYs.
Furthermore, in addition to direct patient ben-
efits, an important consideration in identifying
optimal treatment sequences is the impact a
treatment sequence may have on hospital
capacity. Our analyses indicated that the
capacity required over time is dependent on the
choice of sequence, with resource use peaking
10–15 years after treatment initiation. The
required capacity is presented in terms of the
number of patients on each of the treatments
requiring infusion visits. However, this may not
be a clear indicator of the capacity required in
the hospital as it is unlikely that all these
patients would require their infusion visit at the
same time. It is therefore important to consider
treatment schedules along with the operating
hours of the units.
It should be noted that the choice of the
base-case treatment guidelines using the NHS
treatment algorithm [34] may not be represen-
tative of the treatment sequence used in prac-
tice. A change in the treatment guidelines
sequence will have a subsequent impact on the
relative costs and benefits of the other sequen-
ces compared to it. Furthermore, these analyses
focused on the relative benefits of treatment
sequences for the first three treatment lines, in
order to compare the results to the NHS treat-
ment algorithm which gave no clear informa-
tion on treatments that should be used in the
fourth and subsequent treatment line [34]. In
addition, there was limited information on the
effectiveness of treatments when given in later
treatment lines [17, 35, 37]. This lack of infor-
mation adds some strength to our decision to
concentrate on the first three treatment lines.
Alternatively, focusing on the first three treat-
ment lines may underestimate the treatment
benefits to the extent that improvement could
appear in later lines. An example of this is when
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patients are given less efficacious and less costly
treatments in earlier treatment lines. Those
patients with more severe RRMS would likely
switch away from these treatments quickly to
more effective and costly treatments, whereas
patients with milder RRMS may stay on these
earlier treatment lines for longer. Furthermore,
as the benefits of the treatment are deferred
until later lines for the more severe patients,
this would mean that the total number of
QALYs gained from the treatment sequence
would be increased, impacting the value of the
cost-effectiveness scenario.
CONCLUSIONS
From a validation perspective, the model
proved to be robust in generating outcomes
consistent with existing RRMS models and
published studies on natural history. This
approach can be used to identify optimal
treatment sequences for patients with RRMS
using different decision criteria. Improvements
to the current treatment guidelines sequence in
terms of the proportion of patients reaching
EDSS6 after three lines of treatment and quality
of life outcomes were possible. However, this
comes at both a financial and capacity cost.
Moving forward, this innovative framework has
the potential to reliably simulate individual
patient trajectories in the current complicated
treatment landscape and therefore may prove
useful to support treatment switching, treat-
ment positioning, and treatment guideline
decisions in RRMS.
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